journal
https://read.qxmd.com/read/39043965/correction-a-novel-lncrna-snhg29-regulates-ep300-related-histone-acetylation-modification-and-inhibits-flt3-itd-aml-development
#1
Shan Liu, Jie Zhou, Xiangling Ye, Danni Chen, Weimin Chen, Yaobin Lin, Zhizhong Chen, Biyun Chen, Jin Shang
No abstract text is available yet for this article.
July 23, 2024: Leukemia
https://read.qxmd.com/read/39043964/in-vivo-crispr-cas9-mediated-screen-reveals-a-critical-function-of-tfdp1-and-e2f4-transcription-factors-in-hematopoiesis
#2
JOURNAL ARTICLE
Ngoc Tung Tran, Robin Graf, Ernesto Acevedo-Ochoa, Janine Trombke, Timm Weber, Thomas Sommermann, Claudia Salomon, Ralf Kühn, Klaus Rajewsky, Van Trung Chu
Hematopoiesis is a continuous process of blood cell production driven by hematopoietic stem and progenitor cells (HSPCs) in the bone marrow. Proliferation and differentiation of HSPCs are regulated by complex transcriptional networks. In order to identify transcription factors with key roles in HSPC-mediated hematopoietic reconstitution, we developed an efficient and robust CRISPR/Cas9-based in vivo genetic screen. Using this experimental system, we identified the TFDP1 transcription factor to be essential for HSPC proliferation and post-transplant hematopoiesis...
July 23, 2024: Leukemia
https://read.qxmd.com/read/39043963/improved-outcome-of-covid-19-over-time-in-patients-treated-with-car-t-cell-therapy-update-of-the-european-covid-19-multicenter-study-on-behalf-of-the-european-society-for-blood-and-marrow-transplantation-ebmt-infectious-diseases-working-party-idwp-and-the-european
#3
JOURNAL ARTICLE
Anne Mea Spanjaart, Per Ljungman, Gloria Tridello, Juana Schwartz, Nuria Martinez-Cibrián, Pere Barba, Mi Kwon, Lucia Lopez-Corral, Joaquin Martinez-Lopez, Christelle Ferra, Roberta Di Blasi, Hervé Ghesquieres, Pim Mutsaers, Friso Calkoen, Margot Jak, Jaap van Doesum, Joost S P Vermaat, Marjolein van der Poel, Johan Maertens, Massimiliano Gambella, Elisabetta Metafuni, Fabio Ciceri, Riccardo Saccardi, Emma Nicholson, Eleni Tholouli, Collin Matthew, Victoria Potter, Adrian Bloor, Caroline Besley, Claire Roddie, Keith Wilson, Arnon Nagler, Antonio Campos, Soeren Lykke Petersen, Frantisek Folber, Peter Bader, Jurgen Finke, Nicolaus Kroger, Nina Knelange, Rafael de La Camara, Marie José Kersten, Stephan Mielke
COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome has improved over time with the primary objective of assessing COVID-19-attributable mortality in the Omicron period of 2022 compared to previous years. Data for this multicenter study were collected using the MED-A and COVID-19 report forms developed by the EBMT. One-hundred-eighty patients were included in the analysis, 39 diagnosed in 2020, 35 in 2021 and 106 in 2022...
July 23, 2024: Leukemia
https://read.qxmd.com/read/39033241/subunit-specific-analysis-of-cohesin-mutant-myeloid-malignancies-reveals-distinct-ontogeny-and-outcomes
#4
JOURNAL ARTICLE
Johann-Christoph Jann, Christopher B Hergott, Marisa Winkler, Yiwen Liu, Benjamin Braun, Anne Charles, Kevin M Copson, Shougat Barua, Manja Meggendorfer, Niroshan Nadarajah, Shai Shimony, Eric S Winer, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Jacqueline S Garcia, Torsten Haferlach, R Coleman Lindsley, Marlise R Luskin, Maximilian Stahl, Zuzana Tothova
Mutations in the cohesin complex components (STAG2, RAD21, SMC1A, SMC3, and PDS5B) are recurrent genetic drivers in myelodysplastic neoplasm (MDS) and acute myeloid leukemia (AML). Whether the different cohesin subunit mutations share clinical characteristics and prognostic significance is not known. We analyzed 790 cohesin-mutant patients from the Dana-Farber Cancer Institute (DFCI) and the Munich Leukemia Laboratory (MLL), 390 of which had available outcome data, and identified subunit-specific clinical, prognostic, and genetic characteristics suggestive of distinct ontogenies...
July 20, 2024: Leukemia
https://read.qxmd.com/read/39030358/silencing-gnas-enhances-hdac3i-efficacy-in-crebbp-wild-type-b-cell-lymphoma
#5
REVIEW
Patrizia Mondello
The genetic era has opened the opportunity of using personalized therapeutic approaches, in part based on targeting genes with somatic mutations. For example, lymphomas harboring the highly recurrent CREBBP mutation show dependency on HDAC3, thus selective inhibition of HDAC3 reversed the epigenetic effects of CREBBP mutation, halted lymphoma growth, and induced MHC class II expression, enabling the T-cells to recognize and kill lymphoma cells. However, CREBBP wild type (WT) cells are less sensitive to this approach...
July 19, 2024: Leukemia
https://read.qxmd.com/read/39025987/retraction-note-mek-inhibition-enhances-abt-737-induced-leukemia-cell-apoptosis-via-prevention-of-erk-activated-mcl-1-induction-and-modulation-of-mcl-1-bim-complex
#6
M Konopleva, M Milella, P Ruvolo, J C Watts, M R Ricciardi, B Korchin, McQueen Teresa, William Bornmann, T Tsao, P Bergamo, D H Mak, W Chen, J McCubrey, A Tafuri, M Andreeff
No abstract text is available yet for this article.
July 18, 2024: Leukemia
https://read.qxmd.com/read/39025986/nudt15-mediated-inflammatory-signaling-contributes-to-divergent-outcomes-in-leukemogenesis-and-hematopoiesis
#7
JOURNAL ARTICLE
Jiachen Wang, Yu Zhang, Lei Li, Liujiao Wang, Shuainan Sun, Bowu Wang, Yanwen Ge, Zhonghui Zhang
NUDT15 encodes nucleotide triphosphate diphosphatase that is responsible for metabolizing purine analog drugs, and its genetic mutation results in severe side effects from thiopurine therapy. However, the functions of Nudt15 in leukemic stem cells (LSCs) and hematopoietic stem cells (HSCs) remain unknown. Here we reveal the Nudt15-regulating self-renewal of both mouse LSCs and HSCs. Our data show that Nudt15 negatively regulates murine leukemogenesis and its deficiency prolongs the survival of murine AML recipients by impairing LSC self-renewal, while Nudt15 ablation markedly enhances mouse HSC regenerative potential and self-renewal...
July 18, 2024: Leukemia
https://read.qxmd.com/read/39025985/proteomic-screening-identifies-pf4-cxcl4-as-a-critical-driver-of-myelofibrosis
#8
JOURNAL ARTICLE
Daniele Capitanio, Francesca R Calledda, Vittorio Abbonante, Daniele Cattaneo, Manuela Moriggi, Bartalucci Niccolò, Cristina Bucelli, Delfina Tosi, Umberto Gianelli, Alessandro Maria Vannucchi, Alessandra Iurlo, Cecilia Gelfi, Alessandra Balduini, Alessandro Malara
Despite increased understanding of the genomic landscape of Myeloproliferative Neoplasms (MPNs), the pathological mechanisms underlying abnormal megakaryocyte (Mk)-stromal crosstalk and fibrotic progression in MPNs remain unclear. We conducted mass spectrometry-based proteomics on mice with Romiplostim-dependent myelofibrosis to reveal alterations in signaling pathways and protein changes in Mks, platelets, and bone marrow (BM) cells. The chemokine Platelet Factor 4 (PF4)/Cxcl4 was up-regulated in all proteomes and increased in plasma and BM fluids of fibrotic mice...
July 18, 2024: Leukemia
https://read.qxmd.com/read/39020062/clinical-and-molecular-characteristics-of-extramedullary-acute-myeloid-leukemias
#9
JOURNAL ARTICLE
Tariq Kewan, Waled S Bahaj, Carmelo Gurnari, Olisaemeka D Ogbue, Sudipto Mukherjee, Anjali Advani, James R Cook, Heesun J Rogers, Hetty E Carraway, Suresh K Balasubramanian, Valeria Visconte, Jaroslaw P Maciejewski
No abstract text is available yet for this article.
July 18, 2024: Leukemia
https://read.qxmd.com/read/39020061/immunofluorescence-microscopy-on-the-blood-smear-identifies-patients-with-myeloproliferative-neoplasms
#10
JOURNAL ARTICLE
Carlo Zaninetti, Leonard Vater, Lars Kaderali, Carl C Crodel, Tina M Schnöder, Jessica Fuhrmann, Leonard Swensson, Jan Wesche, Carmen Freyer, Andreas Greinacher, Florian H Heidel
No abstract text is available yet for this article.
July 17, 2024: Leukemia
https://read.qxmd.com/read/39020060/molecular-relapse-after-first-line-intensive-therapy-in-patients-with-cbf-or-npm1-mutated-acute-myeloid-leukemia-a-filo-study
#11
JOURNAL ARTICLE
Corentin Orvain, Sarah Bertoli, Pierre Peterlin, Yohann Desbrosses, Pierre-Yves Dumas, Alexandre Iat, Marie-Anne Hospital, Martin Carre, Emmanuelle Tavernier, Jérémie Riou, Anne Bouvier, Audrey Bidet, Sylvie Tondeur, Florian Renosi, Marie-Joelle Mozziconacci, Pascale Flandrin-Gresta, Bérengère Dadone-Montaudié, Eric Delabesse, Arnaud Pigneux, Mathilde Hunault-Berger, Christian Recher
Patients with Core-Binding Factor (CBF) and NPM1-mutated acute myeloid leukemia (AML) can be monitored by quantitative PCR after having achieved first complete remission (CR) to detect morphologic relapse and drive preemptive therapy. How to best manage these patients is unknown. We retrospectively analyzed 303 patients with CBF and NPM1-mutated AML, aged 18-60 years, without allogeneic hematopoietic cell transplantation (HCT) in first CR, with molecular monitoring after first-line intensive therapy. Among these patients, 153 (51%) never relapsed, 95 (31%) had molecular relapse (53 received preemptive therapy and 42 progressed to morphologic relapse at salvage therapy), and 55 (18%) had upfront morphologic relapse...
July 17, 2024: Leukemia
https://read.qxmd.com/read/39014198/validation-of-independent-prognostic-significance-of-blast-count-in-a-large-cohort-of-mds-patients
#12
JOURNAL ARTICLE
Raniah Al Amri, Vandana Baloda, Sara A Monaghan, Flavia G Rosado, Erika M Moore, Bryan Rea, Miroslav Djokic, Nidhi Aggarwal, Svetlana A Yatsenko, Nathanael G Bailey
No abstract text is available yet for this article.
July 16, 2024: Leukemia
https://read.qxmd.com/read/39014197/fbxl6-is-a-vulnerability-in-aml-and-unmasks-proteolytic-cleavage-as-a-major-experimental-pitfall-in-myeloid-cells
#13
JOURNAL ARTICLE
Anna Sperk, Antje Gabriel, Daniela Koch, Abirami Augsburger, Victoria Sanchez, David Brockelt, Rupert Öllinger, Thomas Engleitner, Piero Giansanti, Romina Ludwig, Priska Auf der Maur, Wencke Walter, Torsten Haferlach, Irmela Jeremias, Roland Rad, Barbara Steigenberger, Bernhard Kuster, Ruth Eichner, Florian Bassermann
No abstract text is available yet for this article.
July 16, 2024: Leukemia
https://read.qxmd.com/read/39004675/phf6-suppresses-self-renewal-of-leukemic-stem-cells-in-aml
#14
JOURNAL ARTICLE
Sapana S Jalnapurkar, Aishwarya S Pawar, Subin S George, Charles Antony, Patrick Somers, Jason Grana, Victoria K Feist, Sandeep Gurbuxani, Vikram R Paralkar
Acute myeloid leukemia is characterized by uncontrolled proliferation of self-renewing myeloid progenitors accompanied by a differentiation arrest. PHF6 is a chromatin-binding protein mutated in myeloid leukemias, and its isolated loss increases mouse HSC self-renewal without malignant transformation. We report here that Phf6 knockout increases the aggressiveness of Hoxa9-driven AML over serial transplantation, and increases the frequency of leukemia initiating cells. We define the in vivo hierarchy of Hoxa9-driven AML and identify a population that we term the "LIC-e" (leukemia initiating cells enriched) population...
July 14, 2024: Leukemia
https://read.qxmd.com/read/39003397/targeting-cers6-as1-fgfr1-axis-as-synthetic-vulnerability-to-constrain-stromal-cells-supported-proliferation-in-mantle-cell-lymphoma
#15
JOURNAL ARTICLE
Udita Jindal, Mukesh Mamgain, Uttam Kumar Nath, Isha Sharma, Bhaskar Pant, Ankita Sharma, Archita Gupta, Khaliqur Rahman, Sunil Yadav, Manish Pratap Singh, Shaktiprasad Mishra, Chandra Praksah Chaturvedi, Jose Courty, Navin Singh, Seema Gupta, Sanjeev Kumar, Shailendra Prasad Verma, Saumyaranjan Mallick, Ajay Gogia, Sunil Raghav, Jayanta Sarkar, Kinshuk Raj Srivastava, Dipak Datta, Neeraj Jain
The interaction between stromal and tumor cells in tumor microenvironment is a crucial factor in Mantle cell lymphoma (MCL) progression and therapy resistance. We have identified a long non-coding RNA, CERS6-AS1, upregulated in MCL and associated with poor overall survival. CERS6-AS1 expression was elevated in primary MCL within stromal microenvironment and in a subset of MCL cells adhered to stromal layer. These stromal-adhered MCL-subsets exhibited cancer stem cell signatures than suspension counterparts...
July 13, 2024: Leukemia
https://read.qxmd.com/read/38997434/altered-rna-export-by-sf3b1-mutants-confers-sensitivity-to-nuclear-export-inhibition
#16
JOURNAL ARTICLE
Sana Chaudhry, Felipe Beckedorff, Shaista Shabbir Jasdanwala, Tulasigeri M Totiger, Maurizio Affer, Abimbola Eunice Lawal, Skye Montoya, Francesco Tamiro, Olivia Tonini, Alexandra Chirino, Andrew Adams, Anya K Sondhi, Stephen Noudali, Alyssa Mauri Cornista, Miah Nicholls, Jumana Afaghani, Paola Robayo, Daniel Bilbao, Stephen D Nimer, Jose Antonio Rodríguez, Shruti Bhatt, Eric Wang, Justin Taylor
SF3B1 mutations frequently occur in cancer yet lack targeted therapies. Clinical trials of XPO1 inhibitors, selinexor and eltanexor, in high-risk myelodysplastic neoplasms (MDS) revealed responders were enriched with SF3B1 mutations. Given that XPO1 (Exportin-1) is a nuclear exporter responsible for the export of proteins and multiple RNA species, this led to the hypothesis that SF3B1-mutant cells are sensitive to XPO1 inhibition, potentially due to altered splicing. Subsequent RNA sequencing after XPO1 inhibition in SF3B1 wildtype and mutant cells showed increased nuclear retention of RNA transcripts and increased alternative splicing in the SF3B1 mutant cells particularly of genes that impact apoptotic pathways...
July 13, 2024: Leukemia
https://read.qxmd.com/read/38987275/the-rna-helicases-ddx19a-b-modulate-selinexor-sensitivity-by-regulating-mcl1-mrna-nuclear-export-in-leukemia-cells
#17
JOURNAL ARTICLE
Tatsuya Terasaki, Yuichiro Semba, Kensuke Sasaki, Hiroshi Imanaga, Kiyoko Setoguchi, Takuji Yamauchi, Shigeki Hirabayashi, Fumihiko Nakao, Koshi Akahane, Takeshi Inukai, Takaomi Sanda, Koichi Akashi, Takahiro Maeda
Selinexor, a first-in-class exportin1 (XPO1) inhibitor, is an attractive anti-tumor agent because of its unique mechanisms of action; however, its dose-dependent toxicity and lack of biomarkers preclude its wide use in clinical applications. To identify key molecules/pathways regulating selinexor sensitivity, we performed genome-wide CRISPR/Cas9 dropout screens using two B-ALL lines. We identified, for the first time, that paralogous DDX19A and DDX19B RNA helicases modulate selinexor sensitivity by regulating MCL1 mRNA nuclear export...
July 11, 2024: Leukemia
https://read.qxmd.com/read/38987274/health-related-quality-of-life-and-symptoms-of-chronic-myeloid-leukemia-patients-after-discontinuation-of-tyrosine-kinase-inhibitors-results-from-the-euro-ski-trial
#18
JOURNAL ARTICLE
Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Franck E Nicolini, Jiri Mayer, Daniela Zackova, Jeroen J W M Janssen, Panayiotis Panayiotidis, Hanne Vestergaard, Perttu Koskenvesa, Antonio Almeida, Henrik Hjorth-Hansen, Joaquin Martinez-Lopez, Ulla Olsson-Strömberg, Andreas Hochhaus, Marc G Berger, Gabriel Etienne, Hana Klamova, Edgar Faber, Philippe Rousselot, Markus Pfirrmann, Susanne Saussele
Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients who had been on tyrosine kinase inhibitors (TKIs) therapy for at least 3 years and achieved MR4 for at least 1 year were enrolled from 11 European countries, and the EORTC QLQ-C30 and the FACIT-Fatigue questionnaires were used to assess HRQoL and fatigue respectively. Patients were categorized into the following age groups: 18-39, 40-59, 60-69 and ≥70 years...
July 10, 2024: Leukemia
https://read.qxmd.com/read/38982262/hemolytic-versus-malproductive-anemia-in-large-granular-lymphocytic-leukemia
#19
JOURNAL ARTICLE
Olisaemeka Ogbue, Tariq Kewan, Carlos Bravo-Perez, Serhan Unlu, Naomi Kawashima, Nakisha D Williams, Arooj Ahmed, Luca Guarnera, Carmelo Gurnari, Valeria Visconte, Jaroslaw P Maciejewski
No abstract text is available yet for this article.
July 9, 2024: Leukemia
https://read.qxmd.com/read/38982261/myelofibrosis-management-in-routine-clinical-practice-with-a-focus-on-patients-with-cytopenias-recommendations-from-a-global-consensus-group
#20
JOURNAL ARTICLE
Steffen Koschmieder, Prithviraj Bose, Martin H Ellis, Vikas Gupta, Jean-Jacques Kiladjian, John Mascarenhas, Vikram Mathews, Francesco Passamonti, Claire Harrison
No abstract text is available yet for this article.
July 9, 2024: Leukemia
journal
journal
20191
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.